Axoltis Pharma receives authorization to launch SEALS

• Phase II trial will assess efficacy and tolerability of NX210c in Amyotrophic Lateral Sclerosis (ALS) patients 
• 80 patients due to be enrolled with first results expected in early 2026
• NX210c drug candidate allows for promising approach to repairing Blood Brain Barrier (BBB) which is impaired in neurodegenerative diseases such as ALS

Clermont-Ferrand and Lyon, France, April 10, 2024 – Axoltis Pharma, a French biopharmaceutical company dedicated to developing therapeutic solutions for neurodegenerative diseases, today announces the authorization from ANSM, the French agency for the safety of health products, to launch the SEALS study. This phase II clinical trial of drug candidate NX210c in patients with Amyotrophic Lateral Sclerosis (ALS) is the first to target the integrity of the Blood Brain Barrier (BBB).

Read the press release